Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases
作者:Yvonnick Loidreau、Pascal Marchand、Carole Dubouilh-Benard、Marie-Renée Nourrisson、Muriel Duflos、Nadège Loaëc、Laurent Meijer、Thierry Besson
DOI:10.1016/j.ejmech.2012.11.030
日期:2013.1
Novel N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines (1) and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues (2) were designed and prepared for the first time via microwave-accelerated multi-step synthesis. Various anilines were condensed with N′-(2-cyanaryl)-N,N-dimethylformimidamide intermediates obtained by reaction of 3-amino-6-methoxybenzofuran-2-carbonitrile (3) and 3-ami
新型N-芳基-7-甲氧基苯并[ b ]呋喃[3,2 - d ]嘧啶-4-胺(1)及其N-芳基苯并[ b ]噻吩并[3,2 - d ]嘧啶-4-胺类似物(2)首次通过微波加速多步合成进行设计和制备。通过3-氨基-6-甲氧基苯并呋喃-2-腈(3)与3-氨基-6-甲氧基苯并噻吩-2-腈的反应获得的N ′-(2-氰芳基)-N,N-二甲基甲酰胺中间体缩合各种苯胺。(4)前体与二甲基甲酰胺二甲基乙缩醛。估计了最终产物对五种蛋白激酶(CDK5 / p25,CK1δ/ε,GSK3α/β,DYRK1A和CLK1)的抑制力。化合物(2a – z)对于开发CLK1和DYRK1A激酶的新药理双重抑制剂特别有希望。